Market Place
Sourcing Support
FibroGen to Present at H.C. Wainwright 26th Annual Global Conference
03 Sep 2024 //
GLOBENEWSWIRE
AstraZeneca finally drops roxadustat US rights
28 Feb 2024 //
FIERCE PHARMA
FibroGen Regains All Rights to Roxadustat from AstraZeneca in the United States
26 Feb 2024 //
GLOBENEWSWIRE
FibroGen Presents Data from Phase 3 MATTERHORN Trial of Roxadustat
09 Dec 2023 //
GLOBENEWSWIRE
FibroGen faces more trouble in clinic as DMD drug fails phase 3
08 Jun 2023 //
FIERCE BIOTECH
FibroGen, AZ`s anemia drug Evrenzo finally chalks up a win
19 May 2023 //
FIERCE PHARMA
FibroGen Announces Positive Results from Pivotal Phase 3 Trial of Roxadustat
18 May 2023 //
GLOBENEWSWIRE
FibroGen Announces Results for MATTERHORN, a Ph 3 Clinical Study of Roxadustat
05 May 2023 //
GLOBENEWSWIRE
Astellas depreciates FibroGen`s Evrenzo, nixes cell therapy deal
13 Apr 2023 //
FIERCE PHARMA
Adcomm offers mixed vote, recommends GSK`s kidney disease drug in just patient
27 Oct 2022 //
ENDPTS
AZ, FibroGen`s roxadustat holds promise for sickle cell disease
19 Oct 2022 //
FIERCEBIOTECH
FibroGen Announces Completion of Patient Enrollment in MATTERHORN
26 Aug 2022 //
GLOBENEWSWIRE
EU Nephrologists Lead the Way with Adoption of Astellas/FibroGen`s EVRENZO
29 Jun 2022 //
PRNEWSWIRE
FibroGen, Astellas find roxadustat support from NICE
10 Jun 2022 //
FIERCEPHARMA
Roxadustat`s safety passed muster in a pooled analysis
20 May 2022 //
FIERCEPHARMA
Roxa path blocked as AZ remains undecided on what it plans to do post CRL
10 May 2022 //
ENDPTS
AZ, FibroGen clash on roxa`s US path forward in CKD anemia
10 May 2022 //
FIERCEPHARMA
Spherix Uncovers Key Differences in the Management of Chronic Kidney Disease
25 Apr 2022 //
PRNEWSWIRE
SEC pokes around FibroGen`s roxadustat safety data
02 Mar 2022 //
FIERCEPHARMA
AZ, FibroGen try to revive roxa with FDA meeting
11 Nov 2021 //
FIERCEPHARMA
FibroGen cuts jobs as it weighs anemia drug`s future in US
10 Nov 2021 //
BIOPHARMADIVE
GSK pulls off clean sweep of endpoint hits in anemia phase 3
09 Nov 2021 //
FIERCEBIOTECH
GSK`s anemia drug succeeds where AZ-FibroGen, Akebia failed
06 Nov 2021 //
FIERCEPHARMA
FibroGen Announces Analyses from Roxadustat Global Phase 3 Program
25 Oct 2021 //
GLOBENEWSWIRE
FibroGen and Astellas` roxa won its European green light
21 Aug 2021 //
FIERCEPHARMA
Astellas Receives EC Approval for EVRENZO in Symptomatic Anemia of CKD.
19 Aug 2021 //
GLOBENEWSWIRE
Akebia sees first-in-class opening for roxadustat rival: CEO
17 Aug 2021 //
FIERCEPHARMA
FibroGen`s longtime CFO hands baton to J&J veteran
16 Aug 2021 //
FIERCEPHARMA
FDA seeks more trial data on AstraZeneca’s NDA for roxadustat for CKD
12 Aug 2021 //
PHARMABIZ
FDA seeks more trial data on AstraZeneca’s NDA for roxadustat for CKD
12 Aug 2021 //
PHARMABIZ
FibroGen receives FDA complete response letter for roxadustat
10 Aug 2021 //
GLOBENEWSWIRE
Safety concerns push FDA adcomm to vote overwhelmingly against FibroGen`s roxadustat
16 Jul 2021 //
ENDPTS
FibroGen admits to messing with roxadustat safety data, upending hopes
09 Apr 2021 //
FIERCE PHARMA
FibroGen admits to manipulating data for anemia drug roxadustat
07 Apr 2021 //
FIERCEPHARMA
FibroGen shares take a beating as CEO reveals safety data manipulation
06 Apr 2021 //
ENDPTS
FibroGen shares sink as FDA meeting decision suggests another delay for top drug
04 Mar 2021 //
BIOPHARMADIVE
ICER Publishes Evidence Report on Roxadustat for Treating Anemia in CKD
28 Jan 2021 //
ICER
FDA delays AstraZeneca`s roxadustat, dashing hopes for 2020 nod
21 Dec 2020 //
FIERCEPHARMA
Update on US regulatory review of roxadustat in anaemia of CKD
18 Dec 2020 //
ASTRAZENECA
Update on US regulatory review of roxadustat in anaemia of CKD
18 Dec 2020 //
PRESS RELEASE
FibroGen to Present Safety and Efficacy Analyses from Roxadustat
02 Dec 2020 //
GLOBENEWSWIRE
Japan approves Astellas & FibroGen`s Evrenzo for chronic kidney disease patients
28 Nov 2020 //
PHARMAFILE
Astellas Receives Approval of EVRENZO® (roxadustat) in Japan
27 Nov 2020 //
PRNEWSWIRE
Astellas Receives Approval of EVRENZO® (roxadustat) in Japan
26 Nov 2020 //
PRNEWSWIRE
FibroGen’s new PhIII data set it up for quick OK, analysts say. But can it avoid
26 Oct 2020 //
ENDPTS
AZ advances leadership in renal disease with more than 80 abstracts
19 Oct 2020 //
PRESS RELEASE
New Roxadustat Data in Anemia of Chronic Kidney Disease to be Released
19 Oct 2020 //
PRNEWSWIRE
Astellas to present new roxadustat data in anemia of CKD at ASN kidney week
19 Oct 2020 //
BIOSPECTRUMASIA
FibroGen Announces New Roxadustat Data Presented at 2020 ERA-EDTA
08 Jun 2020 //
GLOBENEWSWIRE
Roxadustat Demonstrates Non-Inferiority to Darbepoetin in Phase 3 DOLOMITES
07 Jun 2020 //
PRNEWSWIRE
European Medicines Agency Accepts Astellas` Marketing Authorization Roxadustat
21 May 2020 //
PR NEWSWIRE
Court Says FibroGen’s UK Roxadustat Patents Are Invalid
01 May 2020 //
PINK
Easing concerns, FibroGen, AstraZeneca secure FDA date for their anemia drug
13 Feb 2020 //
ENDPTS
Astellas files new application for expanded use of roxadustat in Japan
01 Feb 2020 //
PMLIVE
New FibroGen CEO Conterno cut his post-Lilly `vacation` short. Why? Roxadustat
14 Jan 2020 //
FIERCE PHARMA
FibroGen Submits NDA to the U.S. FDA for Roxadustat
23 Dec 2019 //
GLOBE NEWSWIRE
AstraZeneca flags appealing pooled safety data on roxa
09 Nov 2019 //
END POINTS
AstraZeneca`s roxadustat boosts haemoglobin levels in two Phase 3 trials
08 Nov 2019 //
BUSINESSWIRE
AZ to Present Pivotal Roxadustat Ph III Data at the American Society Nephrology
30 Oct 2019 //
BUSINESSWIRE
Astellas/FibroGen`s anemia drug for CKD patients approved in Japan
20 Sep 2019 //
ENDPTS
